AI-powered search
Try Polaris, our new AI-powered search!

Can you speak to the efficacy of bimekizumab from the three pivotal head-to-head trials?

Featuring Mark Lebwohl, MD | Senior Clinical Advisor |

Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology
Dean for Clinical Therapeutics at the Icahn School of Medicine, Mount Sinai
New York, NY

| Published October 20, 2023

More from this series

Is there drug monitoring required for bimekizumab?

Psoriasis

Is there drug monitoring required for bimekizumab?

Featuring Mark Lebwohl, MD

What is the dosing regimen for bimekizumab?

Psoriasis

What is the dosing regimen for bimekizumab?

Featuring Mark Lebwohl, MD

How quickly does bimekizumab start working?

Psoriasis

How quickly does bimekizumab start working?

Featuring Mark Lebwohl, MD